dr. reddy's labs glp-1 receptor agonist medications Laboratories has entered the fast-growing therapy segment with the launch of its semaglutide generic, Obeda, for Type 2 diabetes in India's โน1,446 crore market. ๐๐๐๐ ๐๐ฎ๐ฅ๐ฅ ๐๐ซ๐ญ๐ข๐๐ฅ๐ ๐จ๐ง ๐จ๐ฎ๐ซ Dr. Reddy's Laboratories has received
Description
Glucagon-like peptide-1 (GLP-1) agonists are a class of medications that have gained significant attention in recent years for their ability to manage blood sugar levels and promote weight loss
Therefore, therapeutic options that could work in a way other than classic antidepressants are being sought to increase the effectiveness of the treatment
Eligibility criteria Adults (18 years) receiving any approved GLP-1 RA for any indication
Data Synthesis Twenty-two reports and six prescribing sheets were included
